Breaking new ground in immunology to help patients around the world
At MiroBio, we are driven to deliver transformational immunotherapies for people living with immune-mediated inflammatory disease, building on our unique expertise in checkpoint agonist antibody engineering.
Our Leadership
We are bringing together world-class expertise and drug development talent to make MiroBio an innovative force in immunology and turn our vision into a reality. We are united by the promise of an exciting new field and a thriving culture which celebrates scientific rigor, inclusivity, patient-first thinking and collaborative energy.
Lynne Murray, PhD, MBA
Chief Scientific Officer
Lynne Murray, PhD, MBA
Chief Scientific Officer
Dr. Murray has served as Chief Scientific Officer for MiroBio since March 2022, having previously served as Senior Vice President of Research since joining in October 2020. Dr. Murray brings substantial experience in the discovery and development of pharmaceuticals from preclinical to Phase 2 in both large pharmaceutical and small biotech environments. Prior to joining MiroBio she served as Head of Regeneration at AstraZeneca’s early respiratory & immunology department. Over her tenure, she led multiple large and small molecule programs and gained significant business development experience in the partnering & strategy department at AZ. Before this, she was Director of Pharmacology at a U.S.-based biotech, Promedior and also held a research position at Janssen, Philadelphia after her postdoc at UCLA. Dr. Murray received her MBA from Judge Business School of the University of Cambridge and holds a Ph.D. in immunology and pathology from Imperial College London. She is an author of numerous publications and patents.
Simon Davis, PhD
Co-founder, Scientific Advisor
Simon Davis, PhD
Co-founder, Scientific Advisor
Simon Davis is a co-founder and was Founding Director of MiroBio and serves as a key scientific advisor to the Company. As a professor of molecular immunology at the University of Oxford for over 15 years, he has mapped the surface of T-cells and explored the structures of surface proteins while determining how to manipulate immune signaling. This resulted in the seminal proposal of the kinetic-segregation model of receptor triggering. In 1995, Simon established his own laboratory in what is now the Radcliffe Department of Medicine at the University of Oxford. Here he discovered the structural basis of weak, specific recognition at the cell surface, determined the composition of the T-cell surface and overturned the received idea that G protein-coupled receptors are always oligomeric. Simon holds a PhD from Flinders University, Adelaide.
Richard Cornall, MD, PhD, FMedSci
Co-founder, Scientific Advisor
Richard Cornall, MD, PhD, FMedSci
Co-founder, Scientific Advisor
Richard Cornall is a co-founder of MiroBio and supports the research team and provides overall strategic scientific guidance. He has been the Nuffield Professor of Clinical Medicine and head of the Nuffield Department of Medicine (NDM) at the University of Oxford since 2019. The NDM is the largest research department of medicine in Europe and includes centers such as the Jenner Institute and the Wellcome Centre for Human Genetics. Richard is a clinical nephrologist and immunologist whose research interests have focused on the positive and negative selection of lymphocytes, self-tolerance and immune regulation. He studied biochemistry at the University of Cambridge and medicine and genetics at the University of Oxford before training as a junior doctor in London. Richard was a postdoctoral fellow at Stanford University in the Laboratory of Chris Goodnow before he returned to the University of Oxford as a Wellcome Trust Senior Clinical Fellow and professor of immunology.
Jason G. Cyster, PhD
Jason G. Cyster, PhD
Jason Cyster is a professor of microbiology and immunology at the University of California, San Francisco and an investigator at the Howard Hughes Medical Institute, Maryland. Jason is an internationally recognized immunologist and has led the way in defining how cells emigrate from lymphoid organs, a process essential for immune function. Jason received a BSc (Hons) in Biochemistry and Microbiology from the University of Western Australia and earned his PhD from the University of Oxford at the Sir William Dunn School of Pathology. He later became a post-doctoral fellow at the Stanford University Medical Center.
Tomas Mustelin, MD, PhD
Tomas Mustelin, MD, PhD
Tomas Mustelin has been a full professor since 1999 (at 38 years of age) and has published 250 papers. He has over 10 years of industry experience as vice president at Amgen, MedImmune/AstraZeneca and Gilead, where he led research and the preclinical development of novel therapeutics in autoimmune, inflammatory/respiratory diseases and immune-oncology. During that time, he served as the site head for Amgen’s Washington site and head of research at MedImmune. He is now the Herndon and Esther Maury Endowed Professor in Rheumatoid Arthritis, professor of medicine, and interim chief of the Division of Rheumatology at the University of Washington, Seattle. His current research is focused on deciphering the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Tomas received his MD and PhD degrees from the University of Helsinki, Finland, held a post-doctoral research position at Scripps Clinic in La Jolla, California, and has been a licensed physician in the EU since 1991.
Robert Stein, MD, PhD
Robert Stein, MD, PhD
Robert Stein is a deeply experienced R&D leader who has played a significant role in the discovery and development of several marketed drugs, including Promacta, Sustiva and Eliquis. Robert is currently executive vice president, R&D, for Mimedx, a venture partner at Samsara BioCapital and an advisor to universities and companies, including Agenus where he was formerly president of research and development. He serves as a Director for a number of public and private companies and has held various senior leadership positions including head of pharmacology for Merck & Co., chief scientific officer and senior vice president, research for Ligand Pharmaceuticals, executive vice president, research and preclinical development for Dupont Merck, president and chief scientific officer for Incyte Pharmaceuticals, president of Roche Palo Alto and chief executive officer of KineMed. Robert holds an MD and a PhD in physiology & pharmacology from Duke University and is Board certified in anatomic and clinical pathology.
